 Scope (blog) |
In his blood
Scope (blog) “Essentially, we’re working on developing a second antibody that, in combination with rituximab, can help the immune system respond more vigorously to the cancer,” says Levy. “In animals the results are very synergistic and quite remarkable. We hope … |
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R …MarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the…
|
L’associazione bendamustina più rituximab in pazienti con linfoma non-hodgkin
Quelli che… la Farmacia I risultati di uno studio, pubblicato su “The Lancet”, dimostrano che l’associazione bendamustina più rituximab (B-R) in pazienti con linfoma non-Hodgkin indolente e mantellare raddoppia la sopravvivenza libera da progressione di malattia (PFS … |
Exciting Developments in Lymphoma (Lymphnode Cancer) and Myeloma …EIN News (press release)To date, up to 80% of patients with the most common subtype of malignant lymphoma (diffuse large B-cell lymphoma), are cured of this aggressive disease by chemo…
Spectrum Pharmaceuticals Provides Update; Guides 2013 Revenue $160-180MBenzingaThe ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a tar…
Spectrum Pharmaceuticals Provides Corporate UpdateMarketWatch (press release)The ZEVALIN therapeutic regimen consists of two components: rituximab, and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targe…
 Healio |
R-BAC shows promise in mantle cell lymphoma
Healio Combination therapy with cytarabine, bendamustine and rituximab was associated with strong response-related outcomes in mantle cell lymphoma, according to results of a phase 2 study. The researchers investigated the R-BAC combination — cytarabine, … |
Knee Rheumatoid ArthritisNews-Medical.netA newer approach is to use biological agents. TNF inhibitors were the first licensed biological agents including etanercept, infliximab, adalimumab and certolizumab. This was followed by monoclonal antibodies li…
MedscapeCost Restricts RA Drug Access in EuropeMedscapeThe bDMARDs surveyed included infliximab, etanercept, adalimumab, certolizumab pegol, golimumab, abatacept, tocilizumab, and rituximab. The cost of annual treatment with sDMARDs never exceeded GDP,…
SymBio Pharma completes patient enrollment in phase II trial of Treakisym in …pharmabiz.comCurrently, R-CHOP is prescribed as a standard therapy, however, clinical trial results in the U.S. and Europe have shown superiority of the combination of ritu…